Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly reported strong second-quarter earnings, surpassing revenue and EPS estimates driven by robust demand for its weight loss and diabetes drugs, Mounjaro and Zepbound, and subsequently raised its 2025 sales and earnings guidance. However, shares declined over 12% in premarket trading as late-stage trial data for its experimental oral obesity drug, orforglipron, underperformed Wall Street expectations, despite showing over 12% body weight loss. The company also noted its guidance excludes potential impacts from planned U.S. pharmaceutical tariffs and ongoing drug pricing pressures.

Analysis

Eli Lilly reported a dichotomous quarter where exceptional operational performance was overshadowed by a significant pipeline setback. The company surpassed Q2 analyst estimates with adjusted EPS of $6.31 versus a $5.57 consensus and revenue of $15.56 billion against a $14.71 billion expectation, representing a 38% year-over-year increase. This growth was propelled by strong sales of its flagship drugs Mounjaro and Zepbound, with a 46% increase in product volume partially offset by lower realized prices. Reflecting this momentum, management raised its fiscal 2025 guidance for both sales, to a range of $60 billion to $62 billion, and adjusted EPS, to $21.75 to $23.00. However, this positive financial news was eclipsed by late-stage trial data for its experimental oral obesity pill, orforglipron, which failed to meet Wall Street's efficacy expectations despite showing over 12% weight loss. The market reacted sharply to this perceived pipeline weakness, sending shares down over 12% in premarket trading. Furthermore, the company's optimistic guidance notably excludes the potential impact of planned U.S. tariffs and ongoing political pressure for drug price reductions, representing significant unquantified risks to future profitability.

Key Decisions for Investors

• Investors must weigh the company's demonstrated strength in its injectable franchise, underscored by the strong Q2 beat and raised 2025 guidance, against the market's recalibration of future growth following the disappointing trial results for the oral drug orforglipron.
• The significant premarket share price decline of over 12% could offer a more attractive entry point, but this must be balanced with the now-tempered expectations for its oral obesity pipeline.
• Closely monitor political and regulatory developments, as the company's guidance explicitly carves out the material risks of potential U.S. pharmaceutical tariffs and broader drug pricing pressures, which could negatively impact future earnings.